ANGIO-CONRAY
LOE Approachingiothalamate sodium
NDAINJECTIONINJECTABLE
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ANGIO-CONRAY (iothalamate sodium) is clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. First approved in 1996.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANGIO-CONRAY (sodium iothalamate) is a radiolabeled diagnostic agent administered via injection for renal imaging and glomerular filtration rate (GFR) assessment. It works by glomerular filtration without tubular secretion or reabsorption, making it a gold-standard marker of kidney function. The compound is cleared rapidly with an effective half-life of approximately 0.07 days.
LOE Approaching
As a legacy diagnostic product approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams are likely consolidating and focusing on niche clinical segments rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ANGIO-CONRAY offers limited external market growth but provides deep expertise in diagnostic imaging, radiopharmaceutical manufacturing, and regulatory maintenance of mature products. Career progression is constrained by product lifecycle stage; success is measured by operational efficiency, cost management, and market share defense rather than expansion or innovation.
Regulatory Affairs Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.